Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, Bosanac I, Choong N, Scappaticci F, Mancao C, Lenz HJ. Parikh AR, et al. Among authors: knost j. Clin Cancer Res. 2019 May 15;25(10):2988-2995. doi: 10.1158/1078-0432.CCR-18-1221. Epub 2018 Sep 17. Clin Cancer Res. 2019. PMID: 30224341 Free PMC article. Clinical Trial.
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE. Pitot HC, et al. Among authors: knost ja. J Clin Oncol. 1997 Aug;15(8):2910-9. doi: 10.1200/JCO.1997.15.8.2910. J Clin Oncol. 1997. PMID: 9256135 Clinical Trial.
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
Saif MW, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH. Saif MW, et al. Among authors: knost ja. Cancer Chemother Pharmacol. 2016 Oct;78(4):815-24. doi: 10.1007/s00280-016-3134-3. Epub 2016 Aug 26. Cancer Chemother Pharmacol. 2016. PMID: 27566701 Clinical Trial.
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
Peterson AC, Harlin H, Karrison T, Vogelzang NJ, Knost JA, Kugler JW, Lester E, Vokes E, Gajewski TF, Stadler WM; University of Chicago Phase II Consortium. Peterson AC, et al. Among authors: knost ja. Invest New Drugs. 2006 Mar;24(2):141-9. doi: 10.1007/s10637-006-5935-4. Invest New Drugs. 2006. PMID: 16514482 Clinical Trial.
Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
Goldberg RM, Hatfield AK, Kahn M, Sargent DJ, Knost JA, O'Connell MJ, Krook JE, Maillard JA, Wiesenfeld M, Schaefer PL, Tirona MT, Moertel CG. Goldberg RM, et al. Among authors: knost ja. J Clin Oncol. 1997 Nov;15(11):3320-9. doi: 10.1200/JCO.1997.15.11.3320. J Clin Oncol. 1997. PMID: 9363861 Clinical Trial.
44 results